Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Thalassemia
4.2.2 Increasing Awareness of Thalassemia Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Blood Transfusions
5.1.2 Iron Chelation Therapy
5.1.3 Folic Acid Supplements
5.1.4 Others
5.2 By Disease Type
5.2.1 Alpha Thalassemia
5.2.2 Beta Thalassemia
5.3 By End-User
5.3.1 Hospitals
5.3.2 Research Institutes
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bluebird Bio
6.1.2 IONIS Pharmaceuticals
6.1.3 Novartis AG
6.1.4 Bellicum Pharmaceuticals
6.1.5 ApoPharma Inc
6.1.6 Pfizer, Inc.
6.1.7 Acceleron Pharma, Inc.
6.1.8 Kiadis Pharma
6.1.9 SG Phrma Pvt. Lmt.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS